Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 17, 2025

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

Jun 9, 2025

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

May 13, 2025

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 30, 2025

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 28, 2025

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Apr 17, 2025

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 18, 2025

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 10, 2025

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 7, 2025